Orthopaedic & Rheumatologic Institute Outcomes
Surgical Quality Improvement
Total Hip Arthroplasty Outcomes
Total Hip Arthroplasty ACS NSQIP Outcomes
January 1, 2022 – December 31, 2022
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall total hip arthroplasty ACS NSQIP performance benchmarked against 491 participating sites.
| Total Hip Arthroplasty (491 sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 342 | 0.58% | 0.61% |
| 30 Day Morbidity | 342 | 3.51% | 4.65% |
| Cardiac | 342 | 0.88% | 0.61% |
| Pneumonia | 342 | 0.29% | 0.49% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 342 | 1.46% | 0.62% |
| Renal Failure | 342 | 0.58% | 0.46% |
| Urinary Tract Infection (UTI) | 342 | 0.29% | 0.88% |
| Surgical Site Infection (SSI) | 342 | 1.17% | 1.77% |
| Sepsis | 341 | 1.17% | 0.55% |
| C.diff Colitis | 342 | 0.00% | 0.11% |
| Unplanned Reoperation | 342 | 1.75% | 3.26% |
| Unplanned Readmission | 342 | 6.43% | 5.82% |
American College of Surgeons National Surgical Quality Improvement Program, 2023.
ACS NSQIP® Semiannual Report July 3, 2023, Chicago: American College of Surgeons.
